NCT05004311View on ClinicalTrials.gov

The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 27, 2021

Primary Completion Date

July 27, 2023

Study Completion Date

August 10, 2023

Conditions
HealthyRenal Impairment
Interventions
DRUG

Cenerimod

A single oral dose of 0.5 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions

Trial Locations (1)

4250-449

BlueClinical Phase 1 Hospital de Prelado, Porto

All Listed Sponsors
lead

Viatris Innovation GmbH

INDUSTRY

NCT05004311 - The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics | Biotech Hunter | Biotech Hunter